US FDA’s Tidmarsh: Marginal Treatments Do More Harm Than Good

 
• By Sarah Karlin-Smith
  
Large Red arrow curving upward with a businessman pushing it up.
Industry must raise their standards for new drug candidates, US FDA's CDER director said. (Shutterstock)

More from US FDA

More from Agency Leadership